Price Target Update on Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) : 12 Wall Street analysts covering Hologic (NASDAQ:HOLX) believe that the average level the stock could reach for the short term is $42.25. The maximum price target given is $46 and the minimum target for short term is around $38, hence the standard deviation is calculated at $2.56.

Other Equity analysts have also commented on the company shares. Equity Analysts at the Brokerage Firm, Needham, downgrades their rating on the shares of Hologic (NASDAQ:HOLX). Needham has a Hold rating on the shares. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on April 28, 2016.

Hologic (NASDAQ:HOLX): stock turned positive on Thursday. Though the stock opened at $34.42, the bulls momentum made the stock top out at $35.66 level for the day. The stock recorded a low of $34.17 and closed the trading day at $35.62, in the green by 4.43%. The total traded volume for the day was 4,426,927. The stock had closed at $34.11 in the previous days trading.

The company shares have dropped -9.50% from its 1 Year high price. On Aug 18, 2015, the shares registered one year high at $43.00 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $33.92 and the 200 Day Moving Average price is recorded at $35.29. On the companys insider trading activities,The director of Hologic Inc, Levy Lawrence M sold 17,794 shares at $34.41 on June 1, 2016. The Insider selling transaction had a total value worth of $612,292. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.